# Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females

> **NCT02740790** · PHASE2 · COMPLETED · sponsor: **Shanghai Zerun Biotechnology Co.,Ltd** · enrollment: 1200 (actual)

## Conditions studied

- Human Papillomavirus

## Interventions

- **BIOLOGICAL:** HPV vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02740790
- **Lead sponsor:** Shanghai Zerun Biotechnology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2015-09
- **Final completion:** 2017-12
- **Target enrollment:** 1200 (ACTUAL)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02740790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02740790, "Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02740790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*